Stablepharma Ltd
- Company typePrivate
- Founded2012
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Stablepharma Ltd firmographics
Firmographics- Name
- Stablepharma Ltd
- Legal name
- Stablepharma Limited
- Website
- https://stablepharma.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Stablepharma Ltd industry classification
Industry- Product category
- Thermostable Vaccines and Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)
- akta.pro secondary industries
- Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA), Vaccine Cold Chain, Storage & Distribution (HLAIAEAK), Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ)
Keywords
Where Stablepharma Ltd is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Stablepharma Ltd business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Revenue model
- Licensing and Milestone Payments: Development and option-to-license agreements generating milestone payments as products advance through development stages. Revenue flows upon achievement of pre-defined development, regulatory, and commercialization milestones.
- Royalty Revenue: Royalty payments upon commercialization of licensed products. AFT Pharmaceuticals partnership includes milestone and royalty revenue upon commercialisation of anti-infective and oncology injectables.
- Government Grants: Funding from Innovate UK Smart Grants and EIC Accelerator Grant to support clinical development of fridge-free vaccine candidates, particularly SPVX02 for tetanus and diphtheria.
- Vaccine Product Sales: Future revenue from direct sales and distribution of fridge-free vaccines. Stablepharma will own global marketing authorisation for SPVX02 and SPVX06 vaccines and be responsible for registration and sales.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Stablepharma Ltd product offering
Product offeringCore offering
Stablepharma develops and licenses its proprietary StablevaX™ thermostabilization platform, which reformulates existing approved vaccines and pharmaceuticals into fridge-free products stable at 40°C and above using trehalose-based stabilization. Its lead candidates are SPVX02 (fridge-free tetanus-diphtheria adult booster vaccine, currently in Phase 1 clinical trials with database lock in November 2025) and SPVX06 (fridge-free tetanus toxoid vaccine), along with an mRNA-LNP thermostabilization programme. The company generates revenue through B2B development and licensing agreements, milestone payments, royalties, and government grants.
Product overview
Stablepharma Ltd is a UK-based biotech company developing a portfolio of fridge-free vaccines and pharmaceuticals using its proprietary StablevaX™ technology platform. The core offering centers on SPVX02, the world's first fridge-free tetanus-diphtheria vaccine currently in Phase 1 clinical trials, and SPVX06, a fridge-free tetanus vaccine. The StablevaX™ platform enables the reformulation of existing approved vaccines and pharmaceuticals into thermostable products that remain stable without refrigeration at temperatures up to 40°C and above. The company is also advancing an mRNA-LNP thermostabilization programme in partnership with the University of Strathclyde, and has expanded into anti-infective and oncology sterile injectables through a partnership with AFT Pharmaceuticals.
Differentiator
Problem solved
Functional benefit
Products and services
- StablevaX™ Proprietary thermostabilization technology platform that reformulates existing approved vaccines and pharmaceuticals into fridge-free forms stable at temperatures of 40°C and above, using trehalose-based stabilization to eliminate cold-chain requirements. Licensed to and co-developed with pharmaceutical partners.
- SPVX02 The world's first fridge-free tetanus-diphtheria (Td) adult booster vaccine, developed using the StablevaX™ technology platform with bulk antigen supply from BB-NCIPD Ltd (Bul Bio). Currently in Phase 1 clinical trials in the UK, with database lock announced in November 2025 and Phase 2/3 trials in preparation.
- SPVX06 A fridge-free Tetanus Toxoid (TT) vaccine reformulated using StablevaX™ technology from Tetatox vaccine manufactured by Bulbio Ltd (BB-NCIPD). Demonstrated 12-month stability at +40°C/75%RH with full protection and sustained immunogenicity in in-vivo challenge studies.
- StablevaX™-mRNA-LNP Programme Research and development programme focused on thermostabilizing mRNA-LNP vaccines (such as COVID-19 vaccines) using the StablevaX™ platform, including naked mRNA kept stable at 45°C for extended periods. Conducted in partnership with the University of Strathclyde, leveraging world-class lipid nanoparticle manufacturing expertise.
Quantifiable outcome
- Vaccines stable at 45°C for 12+ months without potency loss, exceeding WHO requirements of 6 months at 40°C
- +4 more outcomes
Companies that use Stablepharma Ltd
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
Stablepharma Ltd technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Stablepharma Ltd partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, significant and supporting.
- AFT Pharmaceuticals (NZX: AFT; ASX: AFP)coreDevelopment and option-to-license agreement to develop fridge-free sterile injectable medicines targeting anti-infective and oncology treatments in a global market valued at over USD 6 billion. Stablepharma applies StablevaX™ stabilization technology to non-vaccine injectables currently requiring cold-chain storage. Milestone and royalty revenue flows to Stablepharma upon commercialisation. Strategic expansion beyond vaccines enabling both companies to broaden their portfolio of thermostable products.
- AJ VaccinessignificantStrategic Letter of Intent to distribute and commercialise fridge-free vaccines across Europe. Partnership announced December 2024 for European market distribution of SPVX02.
- Thermo Fisher Scientific (PPD)coreWorld-leading sterile manufacturing CDMO partnership. Successfully manufactured and tested 10,000+ vials of SPVX02 under GMP conditions in Monza, Italy. PPD managing Phase 2/3 pivotal trial across approximately 10 sites in UK and Spain. Manufacturing licence approved by AIFA (Italian Regulatory Agency).
- University Hospital Southampton NHS Foundation TrustcoreClinical development partnership for SPVX02 Phase 1 clinical trial led by Professor Saul Faust OBE. Joint Innovate UK grant to advance clinical development, validating safety and efficacy through first-in-human trials. NIHR Southampton Clinical Research Facility serves as primary trial site.
- BB-NCIPD Ltd (Bul Bio)coreBulgarian state-owned vaccine manufacturer (Ministry of Health) with GMP facilities exporting to 100+ countries. Exclusive bulk supply and commercialisation agreement for Tetanus diphtheria vaccine (SPVX02) and Tetanus mono vaccine (SPVX06). Bul Bio supplies bulk vaccine and shares regulatory dossiers; Stablepharma has exclusive rights to manufacture and distribute StablevaX™-Td globally and owns global marketing authorisation. Bul Bio has first right of refusal for Balkans territories and NGOs. One of five WHO pre-qualified Td vaccine suppliers, supplying approximately 9% of global demand.
- University of StrathclydecoreR&D partnership for COVID-19 mRNA vaccine thermo-stabilisation technology. University team provides world-class manufacturing expertise for lipid nanoparticles (LNPs). Collaboration aims to create thermostable mRNA/LNP vaccine analogues similar to vaccines on the market.
- Boyds ConsultantssupportingRegulatory consulting partner pursuing regulatory requirements for reformulated tetanus diphtheria vaccine (SPVX02). Prof. Alan Boyd serves on Stablepharma Advisory Board.
- NIBSC (National Institute for Biological Standards and Control)supportingUK's national institute for biological standards. Collaboration on ELISA assay development validating toxoid integrity for Stability testing.
Scale indicators11 records
Recent moves7 records
Expansion highlights5 records
Stablepharma Ltd competitors and assessment
Company assessmentDirect peers
- Vaxess Technologies: US-based biotech developing a sustained-release vaccine patch platform (including mRNA and flu vaccines) aimed at eliminating cold-chain storage and enabling fridge-stable delivery. Directly comparable to Stablepharma as a vaccine thermostabilization/delivery platform targeting similar LMIC and global public-health customers.
- Micron Biomedical: Clinical-stage developer of dissolvable microneedle array patches for vaccines and therapeutics, designed to remove cold-chain dependency and enable self-administration. Highly comparable product format and value proposition to StablevaX™-enabled fridge-free delivery.
Emerging players
- PharmaJet: Maker of needle-free injection devices (Tropis and Stratis) used for vaccine and therapeutic delivery, including WHO-prequalified needle-free polio immunization campaigns. Comparable as an alternative cold-chain-reducing delivery technology targeting LMIC public-health buyers.
- Exothera: Belgian viral vector and biologics CDMO specializing in process development and GMP manufacturing for vaccines and gene therapies, with public-health mission overlap. Comparable as a scale-up CDMO serving the same LMIC and global health customer base Stablepharma targets.
- Phlow Corp: US-based essential medicines CDMO focused on domestically manufactured active pharmaceutical ingredients and finished sterile injectables, with HHS/ASPR partnerships. Comparable as a public-health-mission drug manufacturer with overlap into sterile injectables, the same adjacency Stablepharma entered via the AFT partnership.
Broad incumbents
- Croda International: Global specialty chemicals company whose life sciences arm supplies vaccine adjuvants, excipients and lipid systems (including for mRNA/LNP formulations). Comparable as an established supplier into vaccine formulation, though far broader than Stablepharma's single thermostable platform.
- BioNTech: mRNA vaccine leader whose Pfizer-partnered COVID-19 vaccine requires ultra-cold storage at -70°C—precisely the cold-chain problem Stablepharma's StablevaX™-mRNA-LNP programme aims to solve. Comparable as the dominant incumbent whose product format Stablepharma seeks to reformulate.
- Bharat Biotech: Major Indian vaccine manufacturer with a broad WHO-prequalified portfolio (rotavirus, typhoid, Td, etc.) where StablevaX™ reformulation could add thermostable versions. Comparable as an emerging-market vaccine manufacturer and a likely licensing/customer target for Stablepharma.
Regional players
- BB-NCIPD (Bul Bio): Bulgarian state-owned vaccine manufacturer and Stablepharma's exclusive bulk supplier for SPVX02/SPVX06, exporting to 100+ countries and supplying ~9% of global Td vaccine demand. Comparable as a regional vaccine manufacturer partnering with Stablepharma, and a potential competitor if it in-houses stabilization.
- AJ Vaccines: Scandinavian vaccine manufacturer (tetanus, diphtheria, BCG, travel vaccines) and Stablepharma's European distribution channel partner. Comparable as a regional vaccine manufacturer whose product portfolio is a candidate for StablevaX™ reformulation and which could emerge as a competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Stablepharma Ltd social profiles
Digital presenceStablepharma Ltd compliance and trust
Trust signalCompliance1 record
Stablepharma Ltd financial estimates
Financial estimateRevenue estimate
Valuation estimate
Stablepharma Ltd leadership team
Management profileNumber of profiles
Profiles23 records
Stablepharma Ltd subsidiaries and ownership
Company hierarchySubsidiaries1 record
Stablepharma Ltd funding detail
Funding detailFunding overview
Funding rounds12 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Stablepharma Ltd M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Stablepharma Ltd
What does Stablepharma Ltd do?
Stablepharma develops and licenses its proprietary StablevaX™ thermostabilization platform, which reformulates existing approved vaccines and pharmaceuticals into fridge-free products stable at 40°C and above using trehalose-based stabilization. Its lead candidates are SPVX02 (fridge-free tetanus-diphtheria adult booster vaccine, currently in Phase 1 clinical trials with database lock in November 2025) and SPVX06 (fridge-free tetanus toxoid vaccine), along with an mRNA-LNP thermostabilization programme. The company generates revenue through B2B development and licensing agreements, milestone payments, royalties, and government grants.
Is Stablepharma Ltd a public or private company?
Stablepharma Ltd is a private company. It is classified as venture growth investor backed and is currently operating.
When was Stablepharma Ltd founded?
Stablepharma Ltd was founded in 2012. It employs 11 to 50 people.
Where is Stablepharma Ltd based?
Stablepharma Ltd is headquartered in London, United Kingdom, in the Europe region.
How does Stablepharma Ltd make money?
Four revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are royalty Revenue, government Grants and vaccine Product Sales.
Who are Stablepharma Ltd's main competitors?
Direct peers on record are Vaxess Technologies and Micron Biomedical. Emerging players are PharmaJet, Exothera and Phlow Corp. Broad incumbents are Croda International, BioNTech and Bharat Biotech. Regional players are BB-NCIPD (Bul Bio) and AJ Vaccines.
Does Stablepharma Ltd have an API?
No public API is recorded for Stablepharma Ltd.
What industry is Stablepharma Ltd in?
Stablepharma Ltd's product category is Thermostable Vaccines and Biopharmaceuticals. Its primary akta.pro industry code is HLAAAEAK, Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release), with a secondary code of HLAAAEAA, Prophylactic Human Vaccines (routine, pediatric, adult). Its NAICS code is 325412 and its SIC code is 2836.